CAR T cell therapy in advanced B‐ALL with heavy disease burden
Abstract In recent years, CD19‐directed chimeric antigen receptor (CAR) T cell therapy has exhibited significant potency for treating pediatric relapsed or refractory B‐cell acute lymphoblastic leukemia (r/r B‐ALL). Nonetheless, many patients with disease progressing rapidly may not benefit from thi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ImmunoMedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imed.1037 |